Welichem Obtains Approval for Phase IIa Clinical Trial on Eczema
Advertisement
Welichem Biotech Inc. announced that Health Canada approved the Company's Clinical Trial Application (CTA) to begin a Phase IIa Clinical Trial of its anti-inflammatory drug candidate, WBI-1001, on atopic dermatitis (a type of eczema).
The Company will initiate its Phase IIa Clinical Trial of WBI-1001 as a topical cream application against atopic dermatitis in the coming months. Atopic dermatitis is normally treated topically with corticosteroids or other immune-suppressors, and these treatments often result in adverse effects after long-term use. WBI-1001 has been developed as a more effective and tolerable topical treatment of this chronic disease.
The Company has completed a Phase I Clinical Trial of this drug candidate on psoriasis, and the clinical data on its safety and efficacy in the Trial should be available by the end of April this year. A Phase II study to confirm and explore its safety and efficacy on psoriasis is planned for mid-2008. Meantime, the Company continues on its rigorous research and development schedule.
Other news from the department research and development
